Paula Cunnea

Dr. Paula Cunnea

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
HLHaonan Lu
Haonan Lu
MAMubarik Arshad
Mubarik Arshad
ATAndrew Thornton
Andrew Thornton
GAGiacomo Avesani
Giacomo Avesani
PCPaula Cunnea
Paula Cunnea
EAEric Ofori Aboagye
Eric Ofori Aboagye
The five-year survival rate of epithelial ovarian cancer (EOC) is approximately 35–40% despite maximal treatment efforts, highlighting a need for stratification biomarkers for personalized treatment. Here we extract 657 quantitative mathematical descriptors from the preoperative CT images of 364 EOC patients at their initial presentation. Using machine learning, we derive a non-invasive summary-statistic of the primary ovarian tumor based on 4 descriptors, which we name “Radiomic Prognostic Vector” (RPV). RPV reliably identifies the 5% of patients with median overall survival less than 2 years, significantly improves established prognostic methods, and is validated in two independent, multi-center cohorts. Furthermore, genetic, transcriptomic and proteomic analysis from two independent datasets elucidate that stromal phenotype and DNA damage response pathways are activated in RPV-stratified tumors. RPV and its associated analysis platform could be exploited to guide personalized therapy of EOC and is potentially transferrable to other cancer types.

1 January 2021 in Cancer Drug Resistance
Verified
Journal Article
Open access
PDF file
NRNatasha Rinne
Natasha Rinne
ECElizabeth L. Christie
Elizabeth L. Christie
AAAnastasia Ardasheva
Anastasia Ardasheva
CKChun Hei Kwok
Chun Hei Kwok
NDNikita Demchenko
Nikita Demchenko
PCPaula Cunnea
Paula Cunnea
Cancer Drug Resistance is an open access journal, focusing on pharmacological aspects of drug resistance and its reversal, molecular mechanisms of drug resistance and drug classes, etc. Both clinical and experimental aspects of drug resistance in cancer are included.

22 May 2023 in Cell Reports Medicine
Verified
Journal Article
Open access
PCPaula Cunnea
Paula Cunnea
ECEdward W. Curry
Edward W. Curry
ECElizabeth L Christie
Elizabeth L Christie
KNKatherine Nixon
Katherine Nixon
CKChun Hei Kwok
Chun Hei Kwok
CFChristina Fotopoulou
Christina Fotopoulou
Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor simpler sympodial evolution. Three distinct tumor evolutionary patterns from primary to relapse are identified, demonstrating recurrent disease may emerge from pre-existing or newly detected clones. Crucially, we identify spatial heterogeneity for clinically actionable homologous recombination deficiency scores and for poor prognosis biomarkers CCNE1 and MYC. Copy-number signature, phenotypic, proteomic, and proliferative-index heterogeneity further highlight HGSOC complexity. This study explores HGSOC evolution and dissemination across space and time, its impact on optimal surgical cytoreductive effort and clinical outcomes, and its consequences for clinical decision-making.

18 December 2021 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
CFChristina Fotopoulou
Christina Fotopoulou
ARAnd Andrea G. Rockall
And Andrea G. Rockall
HLHaonan Lu
Haonan Lu
PLPhilippa Lee
Philippa Lee
GAGiacomo Avesani
Giacomo Avesani
SPSonia Prader
Sonia Prader
Background: Predictive models based on radiomics features are novel, highly promising approaches for gynaecological oncology. Here, we wish to assess the prognostic value of the newly discovered Radiomic Prognostic Vector (RPV) in an independent cohort of high-grade serous ovarian cancer (HGSOC) patients, treated within a Centre of Excellence, thus avoiding any bias in treatment quality. Methods: RPV was calculated using standardised algorithms following segmentation of routine preoperative imaging of patients (n = 323) who underwent upfront debulking surgery (01/2011-07/2018). RPV was correlated with operability, survival and adjusted for well-established prognostic factors (age, postoperative residual disease, stage), and compared to previous validation models. Results: The distribution of low, medium and high RPV scores was 54.2% (n = 175), 33.4% (n = 108) and 12.4% (n = 40) across the cohort, respectively. High RPV scores independently associated with significantly worse progression-free survival (PFS) (HR = 1.69; 95% CI:1.06–2.71; P = 0.038), even after adjusting for stage, age, performance status and residual disease. Moreover, lower RPV was significantly associated with total macroscopic tumour clearance (OR = 2.02; 95% CI:1.56–2.62; P = 0.00647). Conclusions: RPV was validated to independently identify those HGSOC patients who will not be operated tumour-free in an optimal setting, and those who will relapse early despite complete tumour clearance upfront. Further prospective, multicentre trials with a translational aspect are warranted for the incorporation of this radiomics approach into clinical routine.

19 October 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
ACAzadeh Cheraghchi-Bashi
Azadeh Cheraghchi-Bashi
CPChristine A. Parker
Christine A. Parker
ECEd Curry
Ed Curry
JSJean-Frederic Salazar
Jean-Frederic Salazar
HGHatice Gungor
Hatice Gungor
ESEuan A. Stronach
Euan A. Stronach
Our identification of dysregulation of the AKT pathway in ovarian cancer as a platinum resistance specific event led to a comprehensive analysis of in vitro, in vivo and clinical behaviour of the AKT inhibitor GSK2141795. Proteomic biomarker signatures correlating with effects of GSK2141795 were developed using in vitro and in vivo models, well characterised for related molecular, phenotypic and imaging endpoints. Signatures were validated in temporally paired biopsies from patients treated with GSK2141795 in a clinical study. GSK2141795 caused growth-arrest as single agent in vitro, enhanced cisplatin-induced apoptosis in vitro and reduced tumour volume in combination with platinum in vivo. GSK2141795 treatment in vitro and in vivo resulted in ~50-90% decrease in phospho-PRAS40 and 20-80% decrease in fluoro-deoxyglucose (FDG) uptake. Proteomic analysis of GSK2141795 in vitro and in vivo identified a signature of pathway inhibition including changes in AKT and p38 phosphorylation and total Bim, IGF1R, AR and YB1 levels. In patient biopsies, prior to treatment with GSK2141795 in a phase 1 clinical trial, this signature was predictive of post-treatment changes in the response marker CA125. Development of this signature represents an opportunity to demonstrate the clinical importance of AKT inhibition for re-sensitisation of platinum resistant ovarian cancer to platinum.

15 December 2020 in Oncogene
Verified
Journal Article
Closed access
PDF file
MPManikandan Periyasamy
Manikandan Periyasamy
ASAnup K. Singh
Anup K. Singh
CGCarolina Gemma
Carolina Gemma
RFRaed Farzan
Raed Farzan
RARebecca C. Allsopp
Rebecca C. Allsopp
SASimak Ali
Simak Ali